James Chih-Hsin Yang
杨志新
MD, PhD
Director, Department of Oncology; Professor, Graduate Institute of Oncology, National Taiwan University肿瘤科主任；台湾大学肿瘤学研究所教授
👥Biography 个人简介
Global leader in EGFR-targeted therapy clinical trials, particularly in Asian patient populations. Principal investigator for FLAURA (osimertinib vs first-gen TKIs) and multiple LUX-Lung afatinib trials, shaping first-line EGFR TKI standard of care worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
FLAURA Trial Leadership
Served as principal investigator for FLAURA, the landmark phase III trial establishing osimertinib superiority over erlotinib/gefitinib as first-line EGFR TKI therapy, now the global standard of care.
LUX-Lung Afatinib Trials
Led multiple LUX-Lung trials establishing afatinib efficacy against common and uncommon EGFR mutations, defining second-generation TKI role and approved indications across global guidelines.
Representative Works 代表性著作
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (FLAURA)
New England Journal of Medicine (2018)
Definitive phase III trial showing osimertinib PFS superiority (18.9 vs 10.2 months) over standard EGFR TKIs, establishing new standard of care.
Afatinib versus Cisplatin-Based Chemotherapy for EGFR Mutation-Positive Lung Adenocarcinoma (LUX-Lung 3)
Lancet Oncology (2013)
Pivotal trial supporting afatinib approval, demonstrating improved PFS versus chemotherapy in EGFR-mutated NSCLC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 杨志新 的研究动态
Follow James Chih-Hsin Yang's research updates
留下邮箱，当我们发布与 James Chih-Hsin Yang（National Taiwan University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment